Log In
BCIQ
Print this Print this
 

LIV-1205

  Manage Alerts
Collapse Summary General Information
Company Chiome Bioscience Inc.
DescriptionHumanized mAb targeting cell surface antigen DLL1
Molecular Target Delta-like 1 (DLL1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$73.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/26/2015

Undisclosed

0

$73.8M

Get a free BioCentury trial today